Peter ten Dijke

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5857775/publications.pdf

Version: 2024-02-01

488	62,183	511	1051
papers	citations	128 h-index	234 g-index

503	503	503	51332
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	ALK1 controls hepatic vessel formation, angiodiversity, and angiocrine functions in hereditary hemorrhagic telangiectasia of the liver. Hepatology, 2023, 77, 1211-1227.	7.3	5
2	Inhibition of the prolyl isomerase Pin1 improves endothelial function and attenuates vascular remodelling in pulmonary hypertension by inhibiting TGF-Î² signalling. Angiogenesis, 2022, 25, 99-112.	7.2	8
3	The protein kinase LKB1 promotes selfâ€renewal and blocks invasiveness in glioblastoma. Journal of Cellular Physiology, 2022, 237, 743-762.	4.1	8
4	Follistatinâ€controlled activinâ€HNF4Î±â€coagulation factor axis in liver progenitor cells determines outcome of acute liver failure. Hepatology, 2022, 75, 322-337.	7.3	14
5	Combinatorial Therapeutic Approaches with Nanomaterial-Based Photodynamic Cancer Therapy. Pharmaceutics, 2022, 14, 120.	4.5	28
6	RNF12 is regulated by AKT phosphorylation and promotes TGF-Î² driven breast cancer metastasis. Cell Death and Disease, 2022, 13, 44.	6.3	6
7	Spatial proteogenomics reveals distinct and evolutionarily conserved hepatic macrophage niches. Cell, 2022, 185, 379-396.e38.	28.9	343
8	CD161 expression and regulation defines rapidly responding effector CD4+ T cells associated with improved survival in HPV16-associated tumors. , 2022, 10, e003995.		16
9	Development of small macrocyclic kinase inhibitors. Future Medicinal Chemistry, 2022, 14, 389-391.	2.3	3
10	Transforming growth factor-Î² challenge alters the N-, O-, andÂglycosphingolipid glycomes in PaTu-S pancreatic adenocarcinoma cells. Journal of Biological Chemistry, 2022, 298, 101717.	3.4	4
11	Visualizing Dynamic Changes During TGF-Î²-Induced Epithelial to Mesenchymal Transition. Methods in Molecular Biology, 2022, 2488, 47-65.	0.9	3
12	Establishment of Embryonic Zebrafish Xenograft Assays to Investigate TGF-Î² Family Signaling in Human Breast Cancer Progression. Methods in Molecular Biology, 2022, 2488, 67-80.	0.9	1
13	TGFÎ² selects for proâ€stemness over proâ€invasive phenotypes during cancer cell epithelialâ€“mesenchymal transition. Molecular Oncology, 2022, 16, 2330-2354.	4.6	5
14	A Programmable Multifunctional 3D Cancer Cell Invasion Micro Platform. Small, 2022, 18, e2107757.	10.0	4
15	Crystal structures of BMPRII extracellular domain in binary and ternary receptor complexes with BMP10. Nature Communications, 2022, 13, 2395.	12.8	6
16	Microfluidics meets 3D cancer cell migration. Trends in Cancer, 2022, 8, 683-697.	7.4	26
17	OVOL1 inhibits breast cancer cell invasion by enhancing the degradation of TGF-Î² type I receptor. Signal Transduction and Targeted Therapy, 2022, 7, 126.	17.1	15
18	Dynamic Visualization of TGF-Î²/SMAD3 Transcriptional Responses in Single Living Cells. Cancers, 2022, 14, 2508.	3.7	7

#	Article	IF	Citations
19	Photodynamic Therapy in Combination with the Hepatitis B Core Virus-like Particles (HBc VLPs) to Prime Anticancer Immunity for Colorectal Cancer Treatment. Cancers, 2022, 14, 2724.	3.7	8
20	A Programmable Multifunctional 3D Cancer Cell Invasion Micro Platform (Small 20/2022). Small, 2022, 18, .	10.0	0
21	Synthesis and preclinical evaluation of [11C]LR111 and [18F]EW-7197 as PET tracers of the activin-receptor like kinase-5. Nuclear Medicine and Biology, 2022, 112-113, 9-19.	0.6	1
22	TRAF4 Inhibits Bladder Cancer Progression by Promoting BMP/SMAD Signaling. Molecular Cancer Research, 2022, 20, 1516-1531.	3.4	9
23	Vascular defects associated with hereditary hemorrhagic telangiectasia revealed in patient-derived isogenic iPSCs in 3D vessels on chip. Stem Cell Reports, 2022, 17, 1536-1545.	4.8	11
24	<scp>USP8</scp> promotes cancer progression and extracellular vesicleâ€mediated <scp>CD8</scp>+ T cell exhaustion by deubiquitinating the <scp>TGF</scp>â€Î²2 receptor <scp>TÎ²RII</scp>. EMBO Journal, 2022, 41, .	7.8	20
25	Role of glycosylation in TGF-Î²2 signaling and epithelial-to-mesenchymal transition in cancer. Protein and Cell, 2021, 12, 89-106.	11.0	40
26	E3 Ubiquitin Ligases: Key Regulators of TGFÎ² Signaling in Cancer Progression. International Journal of Molecular Sciences, 2021, 22, 476.	4.1	18
27	A comprehensive enhancer screen identifies TRAM2 as a key and novel mediator of YAP oncogenesis. Genome Biology, 2021, 22, 54.	8.8	16
28	Targeting TGFÎ² signal transduction for cancer therapy. Signal Transduction and Targeted Therapy, 2021, 6, 8.	17.1	186
29	TGF-β-mediated Endothelial to Mesenchymal Transition (EndMT) and the Functional Assessment of EndMT Effectors using CRISPR/Cas9 Gene Editing. Journal of Visualized Experiments, 2021, , .	0.3	5
30	TGF-Î²-Induced Endothelial to Mesenchymal Transition Is Determined by a Balance Between SNAIL and ID Factors. Frontiers in Cell and Developmental Biology, 2021, 9, 616610.	3.7	18
31	Challenges and Opportunities for Drug Repositioning in Fibrodysplasia Ossificans Progressiva. Biomedicines, 2021, 9, 213.	3.2	8
32	Endothelium-derived stromal cells contribute to hematopoietic bone marrow niche formation. Cell Stem Cell, 2021, 28, 653-670.e11.	11.1	31
33	An Experimental Liver Metastasis Mouse Model Suitable for Short and Longâ€Term Intravital Imaging. Current Protocols, 2021, 1, e116.	2.9	4
34	Inhibiting Endothelial Cell Function in Normal and Tumor Angiogenesis Using BMP Type I Receptor Macrocyclic Kinase Inhibitors. Cancers, 2021, 13, 2951.	3.7	4
35	Fine-tuning ALK1 linear polyubiquitination to control angiogenesis. Trends in Cell Biology, 2021, 31, 705-707.	7.9	1
36	Cripto favors chondrocyte hypertrophy via <scp>TGF</scp>â€Î²2 <scp>SMAD1</scp>/5 signaling during development of osteoarthritis. Journal of Pathology, 2021, 255, 330-342.	4.5	11

#	Article	IF	Citations
37	Metabolic Reprogramming of Mammary Epithelial Cells during TGF-Î²-Induced Epithelial-to-Mesenchymal Transition. Metabolites, 2021, 11, 626.	2.9	7
38	Therapeutic targeting of TGF-Î² in cancer: hacking a master switch of immune suppression. Clinical Science, 2021, 135, 35-52.	4.3	42
39	The polarity protein Par3 coordinates positively self-renewal and negatively invasiveness in glioblastoma. Cell Death and Disease, 2021, 12, 932.	6.3	5
40	Breast cancer dormancy is associated with a 4NG1 state and not senescence. Npj Breast Cancer, 2021, 7, 140.	5.2	9
41	Fibrodysplasia Ossificans Progressiva: What Have We Achieved and Where Are We Now? Follow-up to the 2015 Lorentz Workshop. Frontiers in Endocrinology, 2021, 12, 732728.	3.5	15
42	Cancer associated-fibroblast-derived exosomes in cancer progression. Molecular Cancer, 2021, 20, 154.	19.2	116
43	TGF-Î² Pathway. , 2021, , 1485-1497.		0
44	VprBP mitigates TGF-Î² and Activin signaling by promoting Smurf1-mediated type I receptor degradation. Journal of Molecular Cell Biology, 2020, 12, 138-151.	3.3	10
45	THG-1 suppresses SALL4 degradation to induce stemness genes and tumorsphere formation through antagonizing NRBP1 in squamous cell carcinoma cells. Biochemical and Biophysical Research Communications, 2020, 523, 307-314.	2.1	4
46	TGFÎ²-induced metabolic reprogramming during epithelial-to-mesenchymal transition in cancer. Cellular and Molecular Life Sciences, 2020, 77, 2103-2123.	5.4	152
47	Deubiquitinase Activity Profiling Identifies UCHL1 as a Candidate Oncoprotein That Promotes TGFÎ²-Induced Breast Cancer Metastasis. Clinical Cancer Research, 2020, 26, 1460-1473.	7.0	92
48	Current perspectives on inhibitory SMAD7 in health and disease. Critical Reviews in Biochemistry and Molecular Biology, 2020, 55, 691-715.	5.2	37
49	TGFâ€Î² signaling in liver metastasis. Clinical and Translational Medicine, 2020, 10, e160.	4.0	23
50	Reactivation of BMP signaling by suboptimal concentrations of MEK inhibitor and FK506 reduces organ-specific breast cancer metastasis. Cancer Letters, 2020, 493, 41-54.	7.2	17
51	Mechanotransduction is a context-dependent activator of TGF-Î² signaling in mesenchymal stem cells. Biomaterials, 2020, 259, 120331.	11.4	26
52	Small-Molecule Activity-Based Probe for Monitoring Ubiquitin C-Terminal Hydrolase L1 (UCHL1) Activity in Live Cells and Zebrafish Embryos. Journal of the American Chemical Society, 2020, 142, 16825-16841.	13.7	46
53	Cercosporamide inhibits bone morphogenetic protein receptor type I kinase activity in zebrafish. DMM Disease Models and Mechanisms, 2020, 13, .	2.4	7
54	TGF-Î²-Induced Endothelial to Mesenchymal Transition in Disease and Tissue Engineering. Frontiers in Cell and Developmental Biology, 2020, 8, 260.	3.7	133

#	Article	IF	Citations
55	Secreted BMP antagonists and their role in cancer and bone metastases. Bone, 2020, 137, 115455.	2.9	16
56	MnTBAP Reverses Pulmonary Vascular Remodeling and Improves Cardiac Function in Experimentally Induced Pulmonary Arterial Hypertension. International Journal of Molecular Sciences, 2020, 21, 4130.	4.1	2
57	Bone morphogenetic protein receptors: Structure, function and targeting by selective small molecule kinase inhibitors. Bone, 2020, 138, 115472.	2.9	65
58	Differential O- and Glycosphingolipid Glycosylation in Human Pancreatic Adenocarcinoma Cells With Opposite Morphology and Metastatic Behavior. Frontiers in Oncology, 2020, 10, 732.	2.8	16
59	A Signaling Crosstalk between BMP9 and HGF/c-Met Regulates Mouse Adult Liver Progenitor Cell Survival. Cells, 2020, 9, 752.	4.1	10
60	Immunotherapeutic Potential of TGF-Î² Inhibition and Oncolytic Viruses. Trends in Immunology, 2020, 41, 406-420.	6.8	55
61	Mutant ACVR1 Arrests Glial Cell Differentiation to Drive Tumorigenesis in Pediatric Gliomas. Cancer Cell, 2020, 37, 308-323.e12.	16.8	56
62	On-Target Anti-TGF-Î² Therapies Are Not Succeeding in Clinical Cancer Treatments: What Are Remaining Challenges?. Frontiers in Cell and Developmental Biology, 2020, 8, 605.	3.7	127
63	TGFÎ² and EGF signaling orchestrates the AP-1- and p63 transcriptional regulation of breast cancer invasiveness. Oncogene, 2020, 39, 4436-4449.	5.9	52
64	Tacrolimus-Induced BMP/SMAD Signaling Associates With Metabolic Stressâ€“Activated FOXO1 to Trigger Î²-Cell Failure. Diabetes, 2020, 69, 193-204.	0.6	20
65	Development of a 96-well plate sample preparation method for integratedN- andO-glycomics using porous graphitized carbon liquid chromatography-mass spectrometry. Molecular Omics, 2020, 16, 355-363.	2.8	47
66	Designed nanomolar small-molecule inhibitors of Ena/VASP EVH1 interaction impair invasion and extravasation of breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 29684-29690.	7.1	21
67	Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells. Journal of Visualized Experiments, 2020, , .	0.3	11
68	TGF-Î² Pathway. , 2020, , 1-13.		0
69	Controlling Smad4 signaling with a Wip. EMBO Reports, 2020, 21, e50246.	4.5	1
70	Uncovering the deubiquitinase activity landscape of breast cancer. Oncoscience, 2020, 7, 85-87.	2.2	0
71	Uncovering the deubiquitinase activity landscape of breast cancer. Oncoscience, 2020, 7, 85-87.	2.2	0
72	The therapeutic potential of targeting the endothelial-to-mesenchymal transition. Angiogenesis, 2019, 22, 3-13.	7.2	77

#	Article	IF	Citations
73	Autophagy contributes to BMP type 2 receptor degradation andÂdevelopment of pulmonary arterial hypertension. Journal of Pathology, 2019, 249, 356-367.	4.5	30
74	Prevention of progression of pulmonary hypertension by the Nur77 agonist 6-mercaptopurine: role of BMP signalling. European Respiratory Journal, 2019, 54, 1802400.	6.7	25
75	In vivo imaging of TGFÎ² signalling components using positron emission tomography. Drug Discovery Today, 2019, 24, 2258-2272.	6.4	6
76	GREM1 is associated with metastasis and predicts poor prognosis in ER-negative breast cancer patients. Cell Communication and Signaling, 2019, 17, 140.	6.5	32
77	Generation of Fibrodysplasia ossificans progressiva and control integration free iPSC lines from periodontal ligament fibroblasts. Stem Cell Research, 2019, 41, 101639.	0.7	7
78	Development of Macrocycle Kinase Inhibitors for ALK2 Using Fibrodysplasia Ossificans Progressivaâ€Derived Endothelial Cells. JBMR Plus, 2019, 3, e10230.	2.7	26
79	Cancer-associated fibroblast-derived Gremlin 1 promotes breast cancer progression. Breast Cancer Research, 2019, 21, 109.	5.0	94
80	c-Met activation leads to the establishment of a TGFÎ²-receptor regulatory network in bladder cancer progression. Nature Communications, 2019, 10, 4349.	12.8	44
81	Role of soluble endoglin in BMP9 signaling. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 17800-17808.	7.1	61
82	Generation of non-standard macrocyclic peptides specifically binding TSC-22 homologous gene-1. Biochemical and Biophysical Research Communications, 2019, 516, 445-450.	2.1	4
83	Epigenetic Reprogramming of TGF-Î² Signaling in Breast Cancer. Cancers, 2019, 11, 726.	3.7	53
84	TGF-Î²-Mediated Epithelial-Mesenchymal Transition and Cancer Metastasis. International Journal of Molecular Sciences, 2019, 20, 2767.	4.1	635
85	DIPG-13. A NOVEL MOUSE MODEL REVEALS UNEXPECTED MECHANISMS OF ACTION OF ACVR1 MUTATIONS IN DIFFUSE INTRINSIC PONTINE GLIOMA. Neuro-Oncology, 2019, 21, ii71-ii71.	1.2	0
86	Combined Inhibition of TGF-Î² Signaling and the PD-L1 Immune Checkpoint Is Differentially Effective in Tumor Models. Cells, 2019, 8, 320.	4.1	82
87	JNK-Dependent cJun Phosphorylation Mitigates TGFÎ²- and EGF-Induced Pre-Malignant Breast Cancer Cell Invasion by Suppressing AP-1-Mediated Transcriptional Responses. Cells, 2019, 8, 1481.	4.1	11
88	A Perspective on the Development of TGF-Î² Inhibitors for Cancer Treatment. Biomolecules, 2019, 9, 743.	4.0	138
89	Inflammation induces endothelialâ€toâ€mesenchymal transition and promotes vascular calcification through downregulation of BMPR2. Journal of Pathology, 2019, 247, 333-346.	4.5	123
90	TGF-Î² Family Signaling Pathways in Cellular Dormancy. Trends in Cancer, 2019, 5, 66-78.	7.4	52

#	Article	IF	Citations
91	Bone morphogenetic protein receptor signal transduction in human disease. Journal of Pathology, 2019, 247, 9-20.	4.5	151
92	MnTBAP reduces pulmonary vascular remodeling in experimental pulmonary arterial hypertension. , 2019, , .		0
93	JUNB governs a feed-forward network of TGFÎ² signaling that aggravates breast cancer invasion. Nucleic Acids Research, 2018, 46, 1180-1195.	14.5	77
94	TGF-β family co-receptor function and signaling. Acta Biochimica Et Biophysica Sinica, 2018, 50, 12-36.	2.0	150
95	TGF-Î² Signaling in Control of Cardiovascular Function. Cold Spring Harbor Perspectives in Biology, 2018, 10, a022210.	5.5	238
96	Bone Morphogenetic Proteins in Vascular Homeostasis and Disease. Cold Spring Harbor Perspectives in Biology, 2018, 10, a031989.	5.5	118
97	Endothelialâ€toâ€mesenchymal transition in cardiovascular diseases: Developmental signaling pathways gone awry. Developmental Dynamics, 2018, 247, 492-508.	1.8	120
98	Biphasic Role of TGF-Î² in Cancer Progression: From Tumor Suppressor to Tumor Promotor. , 2018, , 455-455.		2
99	Development of a patient-specific 3-Dimensional cell model to study right heart failure. Journal of Molecular and Cellular Cardiology, 2018, 120, 48.	1.9	0
100	Endoglin Expression on Cancer-Associated Fibroblasts Regulates Invasion and Stimulates Colorectal Cancer Metastasis. Clinical Cancer Research, 2018, 24, 6331-6344.	7.0	138
101	Epithelialâ€“mesenchymal-transition-inducing transcription factors: new targets for tackling chemoresistance in cancer?. Oncogene, 2018, 37, 6195-6211.	5.9	131
102	Bone morphogenetic protein 9 as a key regulator of liver progenitor cells in <scp>DDC</scp>â€induced cholestatic liver injury. Liver International, 2018, 38, 1664-1675.	3.9	26
103	Hepatocyte-specific Smad7 deletion accelerates DEN-induced HCC via activation of STAT3 signaling in mice. Oncogenesis, 2017, 6, e294-e294.	4.9	17
104	Smad2 Phosphorylation in Diabetic Kidney Tubule Epithelial Cells Is Associated with Modulation of Several Transforming Growth Factor-Î² Family Members. Nephron, 2017, 135, 291-306.	1.8	15
105	TMED10 Protein Interferes with Transforming Growth Factor (TGF)-Î² Signaling by Disrupting TGF-Î² Receptor Complex Formation. Journal of Biological Chemistry, 2017, 292, 4099-4112.	3.4	25
106	Targeting TGF-Î² Signaling in Cancer. Trends in Cancer, 2017, 3, 56-71.	7.4	697
107	Fluid shear stress-induced TGF-Î²/ALK5 signaling in renal epithelial cells is modulated by MEK1/2. Cellular and Molecular Life Sciences, 2017, 74, 2283-2298.	5.4	27
108	<scp>USP</scp>4 inhibits <scp>SMAD</scp>4 monoubiquitination and promotes activin and <scp>BMP</scp> signaling. EMBO Journal, 2017, 36, 1623-1639.	7.8	44

#	Article	IF	Citations
109	Bone Morphogenetic Proteins in the Initiation and Progression of Breast Cancer. , 2017, , 409-433.		3
110	FAF1 phosphorylation by AKT accumulates TGF-Î² type II receptor and drives breast cancer metastasis. Nature Communications, 2017, 8, 15021.	12.8	40
111	BMP type II receptor as a therapeutic target in pulmonary arterial hypertension. Cellular and Molecular Life Sciences, 2017, 74, 2979-2995.	5.4	84
112	SUMO-triggered ubiquitination of NR4A1 controls macrophage cell death. Cell Death and Differentiation, 2017, 24, 1530-1539.	11.2	33
113	BMP-9 interferes with liver regeneration and promotes liver fibrosis. Gut, 2017, 66, 939-954.	12.1	107
114	Invasive Behavior of Human Breast Cancer Cells in Embryonic Zebrafish. Journal of Visualized Experiments, 2017, , .	0.3	29
115	A novel role for BMP9 as a negative regulator of oval cell-mediated regeneration in response to liver damage. Journal of Hepatology, 2017, 66, S365.	3.7	0
116	Endoglin as an Important Regulator of Colorectal Cancer Invasion and Metastasis. Gastroenterology, 2017, 152, S87.	1.3	0
117	141 Targeting TGFÎ² signaling in BRAF mutant melanoma. Journal of Investigative Dermatology, 2017, 137, S24.	0.7	0
118	Disparate phospho-Smad2 levels in advanced type 2 diabetes patients with diabetic nephropathy and early experimental db/db mouse model. Renal Failure, 2017, 39, 629-642.	2.1	7
119	Breast cancer metastasis suppressor OTUD1 deubiquitinates SMAD7. Nature Communications, 2017, 8, 2116.	12.8	90
120	TGFÎ²1-induced SMAD2/3 and SMAD1/5 phosphorylation are both ALK5-kinase-dependent in primary chondrocytes and mediated by TAK1 kinase activity. Arthritis Research and Therapy, 2017, 19, 112.	3.5	49
121	New function of the myostatin/activin type I receptor (ALK4) as a mediator of muscle atrophy and muscle regeneration. FASEB Journal, 2017, 31, 238-255.	0.5	24
122	Bone Morphogenetic Protein 9 Protects against Neonatal Hyperoxia-Induced Impairment of Alveolarization and Pulmonary Inflammation. Frontiers in Physiology, 2017, 8, 486.	2.8	31
123	TGF-Î²-Induced Endothelial-Mesenchymal Transition in Fibrotic Diseases. International Journal of Molecular Sciences, 2017, 18, 2157.	4.1	249
124	ALK1Fc Suppresses the Human Prostate Cancer Growth in in Vitro and in Vivo Preclinical Models. Frontiers in Cell and Developmental Biology, 2017, 5, 104.	3.7	3
125	Fish tales: The use of zebrafish xenograft human cancer cell models. Histology and Histopathology, 2017, 32, 673-686.	0.7	20
126	Effects of ALK1Fc treatment on prostate cancer cells interacting with bone and bone cells in bone metastasis models.. Journal of Clinical Oncology, 2017, 35, e16576-e16576.	1.6	0

#	Article	IF	Citations
127	Bone morphogenetic protein 9 protects against neonatal hyperoxia-induced impairment of lung development, inflammation and fibrosis. , 2017, , .		0
128	In Brief: Endothelialâ€toâ€mesenchymal transition. Journal of Pathology, 2016, 238, 378-380.	4.5	57
129	Smad6 determines BMP-regulated invasive behaviour of breast cancer cells in a zebrafish xenograft model. Scientific Reports, 2016, 6, 24968.	3.3	41
130	Inhibition of Activin Signaling Slows Progression of Polycystic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2016, 27, 3589-3599.	6.1	42
131	Emerging regulators of BMP bioavailability. Bone, 2016, 93, 220-221.	2.9	1
132	c-Myb Enhances Breast Cancer Invasion and Metastasis through the Wnt/Î²-Catenin/Axin2 Pathway. Cancer Research, 2016, 76, 3364-3375.	0.9	97
133	Regulation of the TGF-Î² pathway by deubiquitinases in cancer. International Journal of Biochemistry and Cell Biology, 2016, 76, 135-145.	2.8	29
134	Delta-Like Ligand 4 Modulates Liver Damage by Down-Regulating Chemokine Expression. American Journal of Pathology, 2016, 186, 1874-1889.	3.8	28
135	Immunoregulation by members of the TGFÎ² superfamily. Nature Reviews Immunology, 2016, 16, 723-740.	22.7	276
136	Targeting tumour vasculature by inhibiting activin receptor-like kinase (ALK)1 function. Biochemical Society Transactions, 2016, 44, 1142-1149.	3.4	39
137	A current perspective on applications of macrocyclicâ€peptideâ€based highâ€affinity ligands. Biopolymers, 2016, 106, 889-900.	2.4	20
138	New function of the myostatin/activin type I receptor (ALK4) as a mediator of muscle atrophy and muscle regeneration. Neuromuscular Disorders, 2016, 26, S153.	0.6	0
139	Inhibition of TGFÎ² type I receptor activity facilitates liver regeneration upon acute CCl4 intoxication in mice. Archives of Toxicology, 2016, 90, 347-357.	4.2	33
140	Expression of TGFÎ²-family signalling components in ageing cartilage: age-related loss of TGFÎ² and BMP receptors. Osteoarthritis and Cartilage, 2016, 24, 1235-1245.	1.3	38
141	<scp>TGF</scp>â€Î² signalling and liver disease. FEBS Journal, 2016, 283, 2219-2232.	4.7	457
142	The rationale for targeting <scp>TGF</scp>â€Î² in chronic liver diseases. European Journal of Clinical Investigation, 2016, 46, 349-361.	3.4	60
143	Activin Receptor-like Kinase 1 Ligand Trap Reduces Microvascular Density and Improves Chemotherapy Efficiency to Various Solid Tumors. Clinical Cancer Research, 2016, 22, 96-106.	7.0	47
144	Interrogating TGF-Î² Function and Regulation in Endothelial Cells. Methods in Molecular Biology, 2016, 1344, 193-203.	0.9	11

#	Article	IF	Citations
145	Targeting BMP signalling in cardiovascular disease and anaemia. Nature Reviews Cardiology, 2016, 13, 106-120.	13.7	193
146	Determining TGF-Î² Receptor Levels in the Cell Membrane. Methods in Molecular Biology, 2016, 1344, 35-47.	0.9	7
147	Mutational activation of BRAF confers sensitivity to transforming growth factor beta inhibitors in human cancer cells. Oncotarget, 2016, 7, 81995-82012.	1.8	18
148	Towards a cure for Fibrodysplasia ossificans progressiva. Annals of Translational Medicine, 2016, 4, S28-S28.	1.7	10
149	Fibulin-4 deficiency increases TGF-Î² signalling in aortic smooth muscle cells due to elevated TGF-Î²2 levels. Scientific Reports, 2015, 5, 16872.	3.3	22
150	Induced Pluripotent Stem Cells to Model Human Fibrodysplasia Ossificans Progressiva. Stem Cell Reports, 2015, 5, 963-970.	4.8	67
151	The BMP pathway either enhances or inhibits the Wnt pathway depending on the SMAD4 and p53 status in CRC. British Journal of Cancer, 2015, 112, 122-130.	6.4	61
152	Disorganised stroma determined on preâ€treatment breast cancer biopsies is associated with poor response to neoadjuvant chemotherapy: Results from the NEOZOTAC trial. Molecular Oncology, 2015, 9, 1120-1128.	4.6	28
153	A Kinome-Wide Small Interfering RNA Screen Identifies Proviral and Antiviral Host Factors in Severe Acute Respiratory Syndrome Coronavirus Replication, Including Double-Stranded RNA-Activated Protein Kinase and Early Secretory Pathway Proteins. Journal of Virology, 2015, 89, 8318-8333.	3.4	68
154	Signal Transduction: Gain of Activin Turns Muscle into Bone. Current Biology, 2015, 25, R1136-R1138.	3.9	3
155	14-3-3Î¶ Turns TGF-Î² to the Dark Side. Cancer Cell, 2015, 27, 151-153.	16.8	18
156	The high affinity ALK1-ligand BMP9 induces a hypertrophy-like state in chondrocytes that is antagonized by TGFÎ²1. Osteoarthritis and Cartilage, 2015, 23, 985-995.	1.3	26
157	P0430 : Delta like ligand 4 drives liver damage through regulating chemokines. Journal of Hepatology, 2015, 62, S474.	3.7	0
158	Bone morphogenetic protein signaling in bone homeostasis. Bone, 2015, 80, 43-59.	2.9	163
159	SLUG Is Expressed in Endothelial Cells Lacking Primary Cilia to Promote Cellular Calcification. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 616-627.	2.4	44
160	Transforming Growth Factor Î² Signaling in Colorectal Cancer Cells With Microsatellite Instability Despite Biallelic Mutations in TGFBR2. Gastroenterology, 2015, 148, 1427-1437.e8.	1.3	55
161	Genetic depletion and pharmacological targeting of Î±v integrin in breast cancer cells impairs metastasis in zebrafish and mouse xenograft models. Breast Cancer Research, 2015, 17, 28.	5.0	42
162	Clinical Utility Gene Card for: Fibrodysplasia ossificans progressiva. European Journal of Human Genetics, 2015, 23, 1431-1431.	2.8	18

#	Article	IF	Citations
163	Heterozygous disruption of activin receptor-like kinase 1 is associated with increased arterial pressure. DMM Disease Models and Mechanisms, 2015, 8, 1427-39.	2.4	8
164	Bone morphogenetic protein 6 and oxidized low-density lipoprotein synergistically recruit osteogenic differentiation in endothelial cells. Cardiovascular Research, 2015, 108, 278-287.	3.8	73
165	Abstract 1370: Activin receptor-like kinase 1 ligand trap reduces microvascular density and improves chemotherapy efficiency to various solid tumors. , 2015, , .		1
166	Regulatory RNAs controlling vascular (dys)function by affecting TGF-ÃŸ family signalling. EXCLI Journal, 2015, 14, 832-50.	0.7	8
167	Ter94/VCP Is a Novel Component Involved in BMP Signaling. PLoS ONE, 2014, 9, e114475.	2.5	6
168	Nuclear receptor NR4A1 promotes breast cancer invasion and metastasis by activating TGF-Î² signalling. Nature Communications, 2014, 5, 3388.	12.8	156
169	Novel Ex Vivo Culture Method for the Study of Dupuytren's Disease: Effects of TGFÎ² Type 1 Receptor Modulation by Antisense Oligonucleotides. Molecular Therapy - Nucleic Acids, 2014, 3, e142.	5.1	24
170	Wild-type p53 inhibits pro-invasive properties of TGF-Î²3 in breast cancer, in part through regulation of EPHB2, a new TGF-Î² target gene. Breast Cancer Research and Treatment, 2014, 148, 7-18.	2.5	22
171	Targeting TGF-Î² Signaling by Antisense Oligonucleotide-mediated Knockdown of TGF-Î² Type I Receptor. Molecular Therapy - Nucleic Acids, 2014, 3, e156.	5.1	26
172	Time-resolved dissection of early phosphoproteome and ensuing proteome changes in response to TGF-Î². Science Signaling, 2014, 7, rs5.	3.6	39
173	Interaction with colon cancer cells hyperactivates TGF-Î² signaling in cancer-associated fibroblasts. Oncogene, 2014, 33, 97-107.	5.9	216
174	Functionality of Endothelial Cells and Pericytes From Human Pluripotent Stem Cells Demonstrated in Cultured Vascular Plexus and Zebrafish Xenografts. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 177-186.	2.4	172
175	Loss of SMAD4 Alters BMP Signaling to Promote Colorectal Cancer Cell Metastasis via Activation of Rho and ROCK. Gastroenterology, 2014, 147, 196-208.e13.	1.3	150
176	Generation, expansion and functional analysis of endothelial cells and pericytes derived from human pluripotent stem cells. Nature Protocols, 2014, 9, 1514-1531.	12.0	281
177	P348Impaired macrophage polarization in endoglin haplo-insufficiency leading to defective tissue repair is recovered by counter balance the TGFbeta pathway. Cardiovascular Research, 2014, 103, S63.4-S63.	3.8	0
178	Assessment of Functional Competence of Endothelial Cells from Human Pluripotent Stem Cells in Zebrafish Embryos. Methods in Molecular Biology, 2014, 1213, 107-119.	0.9	1
179	ENDOGLIN Is Dispensable for Vasculogenesis, but Required for Vascular Endothelial Growth Factor-Induced Angiogenesis. PLoS ONE, 2014, 9, e86273.	2.5	59
180	Overactive bone morphogenetic protein signaling in heterotopic ossification and Duchenne muscular dystrophy. Cellular and Molecular Life Sciences, 2013, 70, 407-423.	5.4	36

#	Article	IF	Citations
181	TRAF4 Promotes TGF-Î² Receptor Signaling and Drives Breast Cancer Metastasis. Molecular Cell, 2013, 51, 559-572.	9.7	194
182	Differential effects of bone morphogenetic protein 2 and 9 on chondroprotective transforming growth factor B signaling. Osteoarthritis and Cartilage, 2013, 21, S124.	1.3	0
183	TGF-Î² and Cardiovascular Disorders. , 2013, , 297-322.		1
184	Animal models of chronic liver diseases. American Journal of Physiology - Renal Physiology, 2013, 304, G449-G468.	3.4	172
185	Signaling interplay between transforming growth factor-Î² receptor and PI3K/AKT pathways in cancer. Trends in Biochemical Sciences, 2013, 38, 612-620.	7.5	207
186	Identification of enhancers of BMP signaling pathway with cartilage anabolic properties. Osteoarthritis and Cartilage, 2013, 21, S288.	1.3	1
187	Preventive and therapeutic effects of Smad7 on radiation-induced oral mucositis. Nature Medicine, 2013, 19, 421-428.	30.7	73
188	Three-dimensional co-cultures of human endothelial cells and embryonic stem cell-derived pericytes inside a microfluidic device. Lab on A Chip, 2013, 13, 3562.	6.0	135
189	Snail and Slug, key regulators of TGF-Î²-induced EMT, are sufficient for the induction of single-cell invasion. Biochemical and Biophysical Research Communications, 2013, 435, 58-63.	2.1	110
190	Specific interactions between Smad proteins and AP-1 components determine TGFÎ²-induced breast cancer cell invasion. Oncogene, 2013, 32, 3606-3615.	5.9	84
191	UBE2O negatively regulates TRAF6-mediated NF-Î°B activation by inhibiting TRAF6 polyubiquitination. Cell Research, 2013, 23, 366-377.	12.0	69
192	Deficiency for endoglin in tumor vasculature weakens the endothelial barrier to metastatic dissemination. Journal of Experimental Medicine, 2013, 210, 563-579.	8.5	110
193	Transforming Growth Factor-Î² (TGF-Î²)-mediated Connective Tissue Growth Factor (CTGF) Expression in Hepatic Stellate Cells Requires Stat3 Signaling Activation. Journal of Biological Chemistry, 2013, 288, 30708-30719.	3.4	159
194	The prognostic role of TGF-Î² signaling pathway in breast cancer patients. Annals of Oncology, 2013, 24, 384-390.	1.2	65
195	Endoglin for tumor imaging and targeted cancer therapy. Expert Opinion on Therapeutic Targets, 2013, 17, 421-435.	3.4	37
196	Fine-tuning BMP7 signalling in adipogenesis by UBE2O/E2-230K-mediated monoubiquitination of SMAD6. EMBO Journal, 2013, 32, 996-1007.	7.8	72
197	Activin receptor-like kinase 1 as a target for anti-angiogenesis therapy. Expert Opinion on Investigational Drugs, 2013, 22, 1371-1383.	4.1	33
198	Transforming growth factor-Î² signalling controls human breast cancer metastasis in a zebrafish xenograft model. Breast Cancer Research, 2013, 15, R106.	5.0	100

#	Article	IF	Citations
199	Antisense-Oligonucleotide Mediated Exon Skipping in Activin-Receptor-Like Kinase 2: Inhibiting the Receptor That Is Overactive in Fibrodysplasia Ossificans Progressiva. PLoS ONE, 2013, 8, e69096.	2.5	30
200	FK506 activates BMPR2, rescues endothelial dysfunction, and reverses pulmonary hypertension. Journal of Clinical Investigation, 2013, 123, 3600-3613.	8.2	354
201	Anti-Sclerostin Antibody Inhibits Internalization of Sclerostin and Sclerostin-Mediated Antagonism of Wnt/LRP6 Signaling. PLoS ONE, 2013, 8, e62295.	2.5	51
202	Mutational Analysis of Sclerostin Shows Importance of the Flexible Loop and the Cystine-Knot for Wnt-Signaling Inhibition. PLoS ONE, 2013, 8, e81710.	2.5	27
203	Deficiency for endoglin in tumor vasculature weakens the endothelial barrier to metastatic dissemination. Journal of Cell Biology, 2013, 200, i10-i10.	5.2	0
204	Role of Endoglin in Fibrosis and Scleroderma. International Review of Cell and Molecular Biology, 2012, 297, 295-308.	3.2	24
205	Ubiquitin-specific Protease 4 Mitigates Toll-like/Interleukin-1 Receptor Signaling and Regulates Innate Immune Activation. Journal of Biological Chemistry, 2012, 287, 11002-11010.	3.4	75
206	Vanilloid Receptor-1 Regulates Neurogenic Inflammation in Colon and Protects Mice from Colon Cancer. Cancer Research, 2012, 72, 1705-1716.	0.9	50
207	Anti-human Activin Receptor-like Kinase 1 (ALK1) Antibody Attenuates Bone Morphogenetic Protein 9 (BMP9)-induced ALK1 Signaling and Interferes with Endothelial Cell Sprouting. Journal of Biological Chemistry, 2012, 287, 18551-18561.	3.4	90
208	Fas-associated Factor 1 Is a Scaffold Protein That Promotes Î²-Transducin Repeat-containing Protein (Î²-TrCP)-mediated Î²-Catenin Ubiquitination and Degradation. Journal of Biological Chemistry, 2012, 287, 30701-30710.	3.4	32
209	Deregulated Bone Morphogenetic Protein Receptor Signaling Underlies Fibrodysplasia Ossificans Progressiva. Current Pharmaceutical Design, 2012, 18, 4087-4092.	1.9	4
210	TGFÎ² Signaling in Liver Regeneration. Current Pharmaceutical Design, 2012, 18, 4103-4113.	1.9	58
211	TGF-Î² signaling in Duchenne muscular dystrophy. Future Neurology, 2012, 7, 209-224.	0.5	4
212	19 HOW ARE HEPATOCYTES PRIMED FOR TGF-Î² MEDIATED APOPTOSIS? BONE MORPHOGENETIC PROTEIN (BMP)-9 AS DEADLY CO-FACTOR IN VITRO AND IN VIVO. Journal of Hepatology, 2012, 56, S9.	3.7	0
213	A Covalently Dimerized Recombinant Human Bone Morphogenetic Protein-15 Variant Identifies Bone Morphogenetic Protein Receptor Type 1B as a Key Cell Surface Receptor on Ovarian Granulosa Cells. Endocrinology, 2012, 153, 1509-1518.	2.8	42
214	TGF-Î² Signaling in Endothelial-to-Mesenchymal Transition: The Role of Shear Stress and Primary CiliaA Presentation from the Keystone Symposium on Epithelial Plasticity and Epithelial to Mesenchymal Transition, Vancouver, Canada, 21 to 26 January 2011.. Science Signaling, 2012, 5, pt2.	3.6	69
215	655 Studying TGF- Signaling Using a High Resolution, Quantitative Mass Spectrometric Approach. European Journal of Cancer, 2012, 48, S155.	2.8	0
216	Key signaling nodes in mammary gland development and cancer: Smad signal integration in epithelial cell plasticity. Breast Cancer Research, 2012, 14, 204.	5.0	28

#	Article	IF	Citations
217	MED12 Controls the Response to Multiple Cancer Drugs through Regulation of TGF-Î² Receptor Signaling. Cell, 2012, 151, 937-950.	28.9	371
218	USP4 is regulated by AKT phosphorylation and directly deubiquitylates TGF-Î² type I receptor. Nature Cell Biology, 2012, 14, 717-726.	10.3	267
219	Cellâ€type specific regulation of myostatin signaling. FASEB Journal, 2012, 26, 1462-1472.	0.5	57
220	Key role for ubiquitin protein modification in TGFÎ² signal transduction. Upsala Journal of Medical Sciences, 2012, 117, 153-165.	0.9	45
221	RNF12 Controls Embryonic Stem Cell Fate and Morphogenesis in Zebrafish Embryos by Targeting Smad7 for Degradation. Molecular Cell, 2012, 46, 650-661.	9.7	83
222	RNF12 Controls Embryonic Stem Cell Fate and Morphogenesis in Zebrafish Embryos by Targeting Smad7 for Degradation. Molecular Cell, 2012, 47, 330.	9.7	1
223	Wnt/Î²-catenin signaling changes C2C12 myoblast proliferation and differentiation by inducing Id3 expression. Biochemical and Biophysical Research Communications, 2012, 419, 83-88.	2.1	16
224	LRP8 mediates Wnt/Î²-catenin signaling and controls osteoblast differentiation. Journal of Bone and Mineral Research, 2012, 27, 2065-2074.	2.8	47
225	Shear induced collateral artery growth modulated by endoglin but not by <scp>ALK1</scp>. Journal of Cellular and Molecular Medicine, 2012, 16, 2440-2450.	3.6	38
226	The activities of Smad and Gli mediated signalling pathways in high-grade conventional osteosarcoma. European Journal of Cancer, 2012, 48, 3429-3438.	2.8	43
227	Soluble fms-like tyrosine kinase 1 and soluble endoglin are elevated circulating anti-angiogenic factors in pre-eclampsia. Pregnancy Hypertension, 2012, 2, 358-367.	1.4	19
228	TGFÎ² Signaling and Cardiovascular Diseases. International Journal of Biological Sciences, 2012, 8, 195-213.	6.4	87
229	MicroRNA-155 Functions as a Negative Regulator of RhoA Signaling in TGF-Î²-induced Endothelial to Mesenchymal Transition. MicroRNA (Shariqah, United Arab Emirates), 2012, 1, 2-10.	1.2	42
230	TGF-Î² signalling and its role in cancer progression and metastasis. Cancer and Metastasis Reviews, 2012, 31, 553-568.	5.9	367
231	BMP signaling in vascular diseases. FEBS Letters, 2012, 586, 1993-2002.	2.8	236
232	Nonsynonymous variants in theSMAD6gene predispose to congenital cardiovascular malformation. Human Mutation, 2012, 33, 720-727.	2.5	114
233	Regulation of endothelial barrier function by TGFâ€Î² type I receptor ALK5: Potential role of contractile mechanisms and heat shock protein 90. Journal of Cellular Physiology, 2012, 227, 759-771.	4.1	19
234	BMP-7 inhibits TGF-Î²-induced invasion of breast cancer cells through inhibition of integrin Î²3 expression. Cellular Oncology (Dordrecht), 2012, 35, 19-28.	4.4	52

#	Article	IF	Citations
235	Age-dependent alteration of TGF-Î²2 signalling in osteoarthritis. Cell and Tissue Research, 2012, 347, 257-265.	2.9	119
236	Regulation of endothelial cell plasticity by TGF-Î²2. Cell and Tissue Research, 2012, 347, 177-186.	2.9	279
237	TGF-Î²2 in progression of liver disease. Cell and Tissue Research, 2012, 347, 245-256.	2.9	581
238	TGF-Î²2 in aging and disease. Cell and Tissue Research, 2012, 347, 5-9.	2.9	34
239	TGFÎ²2 Signaling and Cardiovascular Diseases. International Journal of Biological Sciences, 2012, 8, 195-213.	6.4	146
240	Abstract 533: Shear-Induced Collateral Artery Growth Modulated by Endoglin but Not by ALK1. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, .	2.4	0
241	Exploring anti-TGF-Î²2 therapies in cancer and fibrosis. Growth Factors, 2011, 29, 140-152.	1.7	134
242	Temporal Smad7 Transgene Induction in Mouse Epidermis Accelerates Skin Wound Healing. American Journal of Pathology, 2011, 179, 1768-1779.	3.8	34
243	O.13 Interference of myostatin and TGF-beta signaling by antisense-mediated exon skipping in ALK4/5 receptors. Neuromuscular Disorders, 2011, 21, 704.	0.6	0
244	FK-506 (Tacrolimus), Identified In A High Throughput Screen To Increase Bmprii Signaling, Prevents Pulmonary Arterial Hypertension (PAH) In Mice With Endothelial Bmprii Deletion. , 2011, , .		1
245	Spheroid Assay to Measure TGF-Î²2-induced Invasion. Journal of Visualized Experiments, 2011, , .	0.3	24
246	Critical role of endoglin in tumor cell plasticity of Ewing sarcoma and melanoma. Oncogene, 2011, 30, 334-345.	5.9	68
247	ALK2 mutation in a patient with Down's syndrome and a congenital heart defect. European Journal of Human Genetics, 2011, 19, 389-393.	2.8	33
248	BMP antagonists enhance myogenic differentiation and ameliorate the dystrophic phenotype in a DMD mouse model. Neurobiology of Disease, 2011, 41, 353-360.	4.4	33
249	Activin A induces a non-fibrotic phenotype in smooth muscle cells in contrast to TGF-Î²2. Experimental Cell Research, 2011, 317, 131-142.	2.6	11
250	TGF-Î²2 Signaling in Breast Cancer Cell Invasion and Bone Metastasis. Journal of Mammary Gland Biology and Neoplasia, 2011, 16, 97-108.	2.7	127
251	The TGF-Î²2/Smad pathway induces breast cancer cell invasion through the up-regulation of matrix metalloproteinase 2 and 9 in a spheroid invasion model system. Breast Cancer Research and Treatment, 2011, 128, 657-666.	2.5	179
252	Elevated transforming growth factor Î²2 and mitogen-activated protein kinase pathways mediate fibrotic traits of Dupuytren's disease fibroblasts. Fibrogenesis and Tissue Repair, 2011, 4, 14.	3.4	55

#	Article	IF	Citations
253	Dual exon skipping in myostatin and dystrophin for Duchenne muscular dystrophy. BMC Medical Genomics, 2011, 4, 36.	1.5	40
254	The dynamic roles of TGFâ€Î² in cancer. Journal of Pathology, 2011, 223, 206-219.	4.5	325
255	Endoglin promotes TGF-Î²/Smad1 signaling in scleroderma fibroblasts. Journal of Cellular Physiology, 2011, 226, 3340-3348.	4.1	67
256	TgfÎ²/Alk5 signaling is required for shear stress induced klf2 expression in embryonic endothelial cells. Developmental Dynamics, 2011, 240, 1670-1680.	1.8	55
257	Biphasic effects of transforming growth factor Î² on bone morphogenetic proteinâ€“induced osteoblast differentiation. Journal of Bone and Mineral Research, 2011, 26, 1178-1187.	2.8	79
258	132 Non-synonymous SMAD6 mutations impaired inhibition of bmp signalling in patients with congenital cardiovascular malformation. Heart, 2011, 97, A75-A75.	2.9	0
259	Fas-associated factor 1 antagonizes Wnt signaling by promoting Î²-catenin degradation. Molecular Biology of the Cell, 2011, 22, 1617-1624.	2.1	46
260	TGFÎ² Activates Mitogen- and Stress-activated Protein Kinase-1 (MSK1) to Attenuate Cell Death*. Journal of Biological Chemistry, 2011, 286, 5003-5011.	3.4	26
261	GSK3Î² inactivation induces apoptosis of leukemia cells by repressing the function of c-Myb. Molecular Biology of the Cell, 2011, 22, 3533-3540.	2.1	47
262	TGF-Î²1/ALK5-induced monocyte migration involves PI3K and p38 pathways and is not negatively affected by diabetes mellitus. Cardiovascular Research, 2011, 91, 510-518.	3.8	38
263	Lack of Primary Cilia Primes Shear-Induced Endothelial-to-Mesenchymal Transition. Circulation Research, 2011, 108, 1093-1101.	4.5	173
264	Controlling angiogenesis by two unique TGF-Î² type I receptor signaling pathways. Histology and Histopathology, 2011, 26, 1219-30.	0.7	68
265	TGF-β Receptor Signaling Pathways in Angiogenesis; Emerging Targets for Anti-Angiogenesis Therapy. Current Pharmaceutical Biotechnology, 2011, 12, 2108-2120.	1.6	62
266	ALK2 R206H mutation linked to fibrodysplasia ossificans progressiva confers constitutive activity to the BMP type I receptor and sensitizes mesenchymal cells to BMP-induced osteoblast differentiation and bone formation. Journal of Bone and Mineral Research, 2010, 25, 1208-1215.	2.8	141
267	Signaling by members of the TGF-Î² family in vascular morphogenesis and disease. Trends in Cell Biology, 2010, 20, 556-567.	7.9	348
268	Elevated TGFÎ²â€“Smad signalling in experimental Pkd1 models and human patients with polycystic kidney disease. Journal of Pathology, 2010, 222, 21-31.	4.5	89
269	Smad2 and Smad3 have opposing roles in breast cancer bone metastasis by differentially affecting tumor angiogenesis. Oncogene, 2010, 29, 1351-1361.	5.9	164
270	Annexin A1 regulates TGF-Î² signaling and promotes metastasis formation of basal-like breast cancer cells. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 6340-6345.	7.1	182

#	Article	IF	Citations
271	Identification of a Key Residue Mediating Bone Morphogenetic Protein (BMP)-6 Resistance to Noggin Inhibition Allows for Engineered BMPs with Superior Agonist Activity. Journal of Biological Chemistry, 2010, 285, 12169-12180.	3.4	105
272	Matrix Metalloproteinase-14 (MT1-MMP)â€“Mediated Endoglin Shedding Inhibits Tumor Angiogenesis. Cancer Research, 2010, 70, 4141-4150.	0.9	231
273	In Situ Proximity Ligation Detection of c-Jun/AP-1 Dimers Reveals Increased Levels of c-Jun/Fra1 Complexes in Aggressive Breast Cancer Cell Lines in Vitro and in Vivo. Molecular and Cellular Proteomics, 2010, 9, 1982-1990.	3.8	21
274	Genetic and pharmacological targeting of activin receptor-like kinase 1 impairs tumor growth and angiogenesis. Journal of Experimental Medicine, 2010, 207, 85-100.	8.5	159
275	Distinct Modes of Inhibition by Sclerostin on Bone Morphogenetic Protein and Wnt Signaling Pathways. Journal of Biological Chemistry, 2010, 285, 41614-41626.	3.4	149
276	Integration of transcriptional signals at the tumor cell invasive front. Cell Cycle, 2010, 9, 2491-2501.	2.6	2
277	Measurement of Constitutive Activity of BMP Type I Receptors. Methods in Enzymology, 2010, 484, 281-293.	1.0	3
278	TMEPAI, a Transmembrane TGF-Î²-Inducible Protein, Sequesters Smad Proteins from Active Participation in TGF-Î² Signaling. Molecular Cell, 2010, 37, 123-134.	9.7	136
279	5-Aminosalicylic acid inhibits TGF-Î²1 signalling in colorectal cancer cells. Cancer Letters, 2010, 287, 82-90.	7.2	20
280	Genetic and pharmacological targeting of activin receptor-like kinase 1 impairs tumor growth and angiogenesis. Journal of Cell Biology, 2010, 188, i1-i1.	5.2	0
281	VEGF and inhibitors of TGFÎ² type-I receptor kinase synergistically promote blood-vessel formation by inducing Î±5-integrin expression. Journal of Cell Science, 2009, 122, 3294-3302.	2.0	90
282	Smad3 Is a Key Nonredundant Mediator of Transforming Growth Factor Î² Signaling in Nme Mouse Mammary Epithelial Cells. Molecular Cancer Research, 2009, 7, 1342-1353.	3.4	25
283	Dominant-Negative ALK2 Allele Associates With Congenital Heart Defects. Circulation, 2009, 119, 3062-3069.	1.6	97
284	Ski coâ€repressor complexes maintain the basal repressed state of the TGFâ€Î² target gene, SMAD7, via HDAC3 and PRMT5. Genes To Cells, 2009, 14, 17-28.	1.2	54
285	TGF-Î² signaling in vascular biology and dysfunction. Cell Research, 2009, 19, 116-127.	12.0	476
286	Poor vessel formation in embryos from knock-in mice expressing ALK5 with L45 loop mutation defective in Smad activation. Laboratory Investigation, 2009, 89, 800-810.	3.7	19
287	Ionizing Radiation Shifts the PAI-1/ID-1 Balance and Activates Notch Signaling in Endothelial Cells. International Journal of Radiation Oncology Biology Physics, 2009, 73, 506-513.	0.8	81
288	T.P.1.04 Dual exon skipping in myostatin and dystrophin as a potential therapy for Duchenne muscular dystrophy. Neuromuscular Disorders, 2009, 19, 577.	0.6	0

#	Article	IF	Citations
289	Endoglin haploinsufficiency reduces radiation-induced fibrosis and telangiectasia formation in mouse kidneys. Radiotherapy and Oncology, 2009, 92, 484-491.	0.6	40
290	Transforming growth factor-beta signaling and tumor angiogenesis. Frontiers in Bioscience - Landmark, 2009, 14, 4848.	3.0	105
291	279 BONE MORPHOGENETIC PROTEIN (BMP)-9: A NEW MEMBER OF THE TGF-Î² SUPERFAMILY WHICH IS SECRETED BY ACTIVATED HEPATIC STELLATE CELLS. Journal of Hepatology, 2009, 50, S110.	3.7	2
292	Autocrine Bone Morphogenetic Protein-9 Signals through Activin Receptor-like Kinase-2/Smad1/Smad4 to Promote Ovarian Cancer Cell Proliferation. Cancer Research, 2009, 69, 9254-9262.	0.9	110
293	Shear stress modulates TGFâ€beta signaling and EMT in endothelial cells. FASEB Journal, 2009, 23, 830.8.	0.5	0
294	Endoglin in angiogenesis and vascular diseases. Angiogenesis, 2008, 11, 79-89.	7.2	291
295	Smad1 pathway is activated in systemic sclerosis fibroblasts and is targeted by imatinib mesylate. Arthritis and Rheumatism, 2008, 58, 2528-2537.	6.7	75
296	ALK1 Opposes ALK5/Smad3 Signaling and Expression of Extracellular Matrix Components in Human Chondrocytes. Journal of Bone and Mineral Research, 2008, 23, 896-906.	2.8	138
297	VE-cadherin is a critical endothelial regulator of TGF-Î² signalling. EMBO Journal, 2008, 27, 993-1004.	7.8	146
298	Transforming Growth Factor Î² and Wound Healing in Human Cholesteatoma. Laryngoscope, 2008, 118, 94-98.	2.0	25
299	Transforming Growth Factor Î²â€“Induced Endothelial-to-Mesenchymal Transition: A Switch to Cardiac Fibrosis?. Trends in Cardiovascular Medicine, 2008, 18, 293-298.	4.9	143
300	The Bone Morphogenetic Protein Pathway Is Inactivated in the Majority of Sporadic Colorectal Cancers. Gastroenterology, 2008, 134, 1332-1341.e3.	1.3	151
301	Two novel type II receptors mediate BMP signalling and are required to establish leftâ€“right asymmetry in zebrafish. Developmental Biology, 2008, 315, 55-71.	2.0	54
302	Osteocyte-Derived Sclerostin Inhibits Bone Formation: Its Role in Bone Morphogenetic Protein and Wnt Signaling. Journal of Bone and Joint Surgery - Series A, 2008, 90, 31-35.	3.0	193
303	L- and S-endoglin differentially modulate TGFÎ²1 signaling mediated by ALK1 and ALK5 in L6E9 myoblasts. Journal of Cell Science, 2008, 121, 913-919.	2.0	105
304	Oral administration of GW788388, an inhibitor of TGF-Î² type I and II receptor kinases, decreases renal fibrosis. Kidney International, 2008, 73, 705-715.	5.2	187
305	Role of TGF- β in the Tumor Stroma. Current Cancer Drug Targets, 2008, 8, 466-472.	1.6	20
306	TGF-Î² Signaling and Vascular Morphogenesis. , 2008, , 507-521.		0

#	Article	IF	Citations
307	BMP-9 signals via ALK1 and inhibits bFGF-induced endothelial cell proliferation and VEGF-stimulated angiogenesis. Journal of Cell Science, 2007, 120, 964-972.	2.0	480
308	Transforming Growth Factor-Î² Receptor Type I-dependent Fibrogenic Gene Program Is Mediated via Activation of Smad1 and ERK1/2 Pathways. Journal of Biological Chemistry, 2007, 282, 10405-10413.	3.4	173
309	Bone Morphogenetic Protein 7 in the Development and Treatment of Bone Metastases from Breast Cancer. Cancer Research, 2007, 67, 8742-8751.	0.9	188
310	KLF2 Suppresses TGF-Î² Signaling in Endothelium Through Induction of Smad7 and Inhibition of AP-1. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 532-539.	2.4	92
311	Induction of Sonic Hedgehog Mediators by Transforming Growth Factor-Î²: Smad3-Dependent Activation of Gli2 and Gli1 Expression In vitro and In vivo. Cancer Research, 2007, 67, 6981-6986.	0.9	359
312	Compensatory signalling induced in the yolk sac vasculature by deletion of TGFÎ² receptors in mice. Journal of Cell Science, 2007, 120, 4269-4277.	2.0	104
313	Signaling by ALK5 mediates TGF-Î²-induced ET-1 expression in endothelial cells: a role for migration and proliferation. Journal of Cell Science, 2007, 120, 1256-1266.	2.0	86
314	BMP7, a Putative Regulator of Epithelial Homeostasis in the Human Prostate, Is a Potent Inhibitor of Prostate Cancer Bone Metastasis in Vivo. American Journal of Pathology, 2007, 171, 1047-1057.	3.8	183
315	TMEPAI, a transmembrane TGF-Î²-inducible protein, sequesters Smad proteins in TGF-Î² signaling. Nature Precedings, 2007, , .	0.1	0
316	SOST expression is restricted to the great arteries during embryonic and neonatal cardiovascular development. Developmental Dynamics, 2007, 236, 606-612.	1.8	41
317	Aberrant Bmp signaling and notochord delamination in the pathogenesis of esophageal atresia. Developmental Dynamics, 2007, 236, 746-754.	1.8	70
318	A rapid and sensitive bioassay to measure bone morphogenetic protein activity. BMC Cell Biology, 2007, 8, 41.	3.0	69
319	Extracellular control of TGFÎ² signalling in vascular development and disease. Nature Reviews Molecular Cell Biology, 2007, 8, 857-869.	37.0	708
320	Negative regulation of TGF-Î² receptor/Smad signal transduction. Current Opinion in Cell Biology, 2007, 19, 176-184.	5.4	351
321	Cell regulation. Current Opinion in Cell Biology, 2007, 19, 109-111.	5.4	0
322	TGF-Î² and BMP7 interactions in tumour progression and bone metastasis. Clinical and Experimental Metastasis, 2007, 24, 609-617.	3.3	111
323	The Tumor Suppressor Smad4 Is Required for Transforming Growth Factor Î²â€“Induced Epithelial to Mesenchymal Transition and Bone Metastasis of Breast Cancer Cells. Cancer Research, 2006, 66, 2202-2209.	0.9	344
324	Methylation of Smad6 by protein arginineN-methyltransferase 1. FEBS Letters, 2006, 580, 6603-6611.	2.8	27

#	Article	IF	Citations
325	A Rate Equation Approach to Elucidate the Kinetics and Robustness of the TGF-Î² Pathway. Biophysical Journal, 2006, 91, 4368-4380.	0.5	50
326	Bone morphogenetic protein signal transduction in bone. Current Medical Research and Opinion, 2006, 22, S7-S11.	1.9	68
327	Smad7-Induced Î²-Catenin Degradation Alters Epidermal Appendage Development. Developmental Cell, 2006, 11, 301-312.	7.0	144
328	Reversible ubiquitination regulates the Smad/TGF-Î² signalling pathway. Biochemical Society Transactions, 2006, 34, 761-763.	3.4	58
329	Smad7 and protein phosphatase 1alpha are critical determinants in the duration of TGF-beta/ALK1 signaling in endothelial cells. BMC Cell Biology, 2006, 7, 16.	3.0	50
330	ELAC2, a putative prostate cancer susceptibility gene product, potentiates TGF-Î²/Smad-induced growth arrest of prostate cells. Oncogene, 2006, 25, 5591-5600.	5.9	55
331	An assay for the determination of biologically active bone morphogenetic proteins using cells transfected with an inhibitor of differentiation promoter-luciferase construct. Analytical Biochemistry, 2006, 349, 78-86.	2.4	52
332	Wnt but Not BMP Signaling Is Involved in the Inhibitory Action of Sclerostin on BMP-Stimulated Bone Formation. Journal of Bone and Mineral Research, 2006, 22, 19-28.	2.8	238
333	Id1 is a critical mediator in TGF-Î²-induced transdifferentiation of rat hepatic stellate cells. Hepatology, 2006, 43, 1032-1041.	7.3	132
334	Endoglin Has a Crucial Role in Blood Cellâ€“Mediated Vascular Repair. Circulation, 2006, 114, 2288-2297.	1.6	124
335	The deubiquitinating enzyme UCH37 interacts with Smads and regulates TGF-Î² signalling. Oncogene, 2005, 24, 8080-8084.	5.9	164
336	New mechanisms of skin innate immunity: ASK1-mediated keratinocyte differentiation regulates the expression of Î²-defensins, LL37, and TLR2. European Journal of Immunology, 2005, 35, 1886-1895.	2.9	66
337	Global Analysis of Smad2/3-Dependent TGF-Î² Signaling in Living Mice Reveals Prominent Tissue-Specific Responses to Injury. Journal of Immunology, 2005, 175, 547-554.	0.8	103
338	Transforming Growth Factor-Î² Signal Transduction in Angiogenesis and Vascular Disorders. Chest, 2005, 128, 585S-590S.	0.8	235
339	TGF-? receptor function in the endothelium. Cardiovascular Research, 2005, 65, 599-608.	3.8	453
340	SOST/sclerostin, an osteocyte-derived negative regulator of bone formation. Cytokine and Growth Factor Reviews, 2005, 16, 319-327.	7.2	325
341	Transforming Growth Factor-Î²1 to the Bone. Endocrine Reviews, 2005, 26, 743-774.	20.1	622
342	Control of bone formation by osteocytes? lessons from the rare skeletal disorders sclerosteosis and van Buchem disease. BoneKEy Osteovision, 2005, 2, 33-38.	0.6	6

#	Article	IF	Citations
343	Spatio-temporal activation of Smad1 and Smad5 in vivo: monitoring transcriptional activity of Smad proteins. Journal of Cell Science, 2004, 117, 4653-4663.	2.0	81
344	Sclerostin Is an Osteocyte-expressed Negative Regulator of Bone Formation, But Not a Classical BMP Antagonist. Journal of Experimental Medicine, 2004, 199, 805-814.	8.5	785
345	Defective paracrine signalling by TGFÎ² in yolk sac vasculature of endoglin mutant mice: a paradigm for hereditary haemorrhagic telangiectasia. Development (Cambridge), 2004, 131, 6237-6247.	2.5	141
346	Nerve growth factor mediates activation of the Smad pathway in PC12 cells. FEBS Journal, 2004, 271, 920-931.	0.2	35
347	Synergy and antagonism between Notch and BMP receptor signaling pathways in endothelial cells. EMBO Journal, 2004, 23, 541-551.	7.8	222
348	Endoglin promotes endothelial cell proliferation and TGF-Î²/ALK1 signal transduction. EMBO Journal, 2004, 23, 4018-4028.	7.8	592
349	New insights into TGF-Î²â€“Smad signalling. Trends in Biochemical Sciences, 2004, 29, 265-273.	7.5	1,097
350	Connective tissue growth factor expression and Smad signaling during mouse heart development and myocardial infarction. Developmental Dynamics, 2004, 231, 542-550.	1.8	95
351	Receptor Serine/Threonine Kinases. , 2004, , 174-180.		0
352	RLP, a novel Ras-like protein, is an immediate-early transforming growth factor-Î² (TGF-Î²) target gene that negatively regulates transcriptional activity induced by TGF-Î². Biochemical Journal, 2004, 383, 187-199.	3.7	15
353	Bone morphogenetic protein receptors and their nuclear effectors in bone formation. , 2004, , 9-44.		3
354	Gene Array Analysis of Bone Morphogenetic Protein Type I Receptor-Induced Osteoblast Differentiation. Journal of Bone and Mineral Research, 2003, 18, 1177-1185.	2.8	55
355	Controlling mesenchymal stem cell differentiation by TGFÎ² family members. Journal of Orthopaedic Science, 2003, 8, 740-748.	1.1	155
356	Distribution of phosphorylated Smad2 identifies target tissues of TGFÎ² ligands in mouse development. Gene Expression Patterns, 2003, 3, 355-360.	0.8	37
357	Smad7 prevents activation of hepatic stellate cells and liver fibrosis in rats. Gastroenterology, 2003, 125, 178-191.	1.3	348
358	Controlling cell fate by bone morphogenetic protein receptors. Molecular and Cellular Endocrinology, 2003, 211, 105-113.	3.2	182
359	Bone morphogenetic protein signalling in NGF-stimulated PC12 cells. Biochemical and Biophysical Research Communications, 2003, 307, 632-639.	2.1	10
360	Activin Receptor-like Kinase (ALK)1 Is an Antagonistic Mediator of Lateral TGFÎ²/ALK5 Signaling. Molecular Cell, 2003, 12, 817-828.	9.7	631

#	Article	IF	Citations
361	Nuclear Factor YY1 Inhibits Transforming Growth Factor Î²- and Bone Morphogenetic Protein-Induced Cell Differentiation. Molecular and Cellular Biology, 2003, 23, 4494-4510.	2.3	153
362	Elucidation of Smad Requirement in Transforming Growth Factor-Î² Type I Receptor-induced Responses. Journal of Biological Chemistry, 2003, 278, 3751-3761.	3.4	189
363	Transforming Growth Factor-Î²1 (TGF-Î²)â€“induced Apoptosis of Prostate Cancer Cells Involves Smad7-dependent Activation of p38 by TGF-Î²-activated Kinase 1 and Mitogen-activated Protein Kinase Kinase 3. Molecular Biology of the Cell, 2003, 14, 529-544.	2.1	213
364	Transforming Growth Factor-Î²1 Mutations in Camurati-Engelmann Disease Lead to Increased Signaling by Altering either Activation or Secretion of the Mutant Protein. Journal of Biological Chemistry, 2003, 278, 7718-7724.	3.4	102
365	dSmurf Selectively Degrades Decapentaplegic-activated MAD, and Its Overexpression Disrupts Imaginal Disc Development. Journal of Biological Chemistry, 2003, 278, 26307-26310.	3.4	44
366	Smad protein and TGF-Î² signaling in vascular smooth muscle cells. International Journal of Molecular Medicine, 2003, 11, 645.	4.0	12
367	Growth Differentiation Factor-9 Induces Smad2 Activation and Inhibin B Production in Cultured Human Granulosa-Luteal Cells. Journal of Clinical Endocrinology and Metabolism, 2003, 88, 755-762.	3.6	113
368	SIGNAL TRANSDUCTION OF BONE MORPHOGENETIC PROTEINS IN OSTEOBLAST DIFFERENTIATION. Journal of Bone and Joint Surgery - Series A, 2003, 85, 34-38.	3.0	90
369	Transient Disruption of Autocrine TGF-Î² Signaling Leads to Enhanced Survival and Proliferation Potential in Single Primitive Human Hemopoietic Progenitor Cells. Journal of Immunology, 2002, 168, 755-762.	0.8	46
370	Stimulation of Id1 Expression by Bone Morphogenetic Protein Is Sufficient and Necessary for Bone Morphogenetic Proteinâ€“Induced Activation of Endothelial Cells. Circulation, 2002, 106, 2263-2270.	1.6	280
371	Deficient Smad7 expression: A putative molecular defect in scleroderma. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 3908-3913.	7.1	229
372	Identification and Functional Characterization of Distinct Critically Important Bone Morphogenetic Protein-specific Response Elements in the Id1 Promoter. Journal of Biological Chemistry, 2002, 277, 4883-4891.	3.4	771
373	Immunohistochemical Localization of Osteogenetic Protein (OP-1) and Its Receptors in Rabbit Articular Cartilage. Journal of Histochemistry and Cytochemistry, 2002, 50, 1341-1349.	2.5	20
374	Activation of Bone Morphogenetic Protein/Smad Signaling in Bronchial Epithelial Cells during Airway Inflammation. American Journal of Respiratory Cell and Molecular Biology, 2002, 27, 160-169.	2.9	117
375	BMP Pathways Are Involved in Otic Capsule Formation and Epithelialâ€“Mesenchymal Signaling in the Developing Chicken Inner Ear. Developmental Biology, 2002, 251, 380-394.	2.0	79
376	Engagement of activin and bone morphogenetic protein signaling pathway Smad proteins in the induction of inhibin B production in ovarian granulosa cells. Molecular and Cellular Endocrinology, 2002, 195, 79-88.	3.2	22
377	Physical and Functional Interaction between GATA-3 and Smad3 Allows TGF-Î² Regulation of GATA Target Genes. Current Biology, 2002, 12, 35-45.	3.9	87
378	Action Range of BMP Is Defined by Its N-Terminal Basic Amino Acid Core. Current Biology, 2002, 12, 205-209.	3.9	162

#	Article	IF	Citations
379	Regulation of cell proliferation by Smad proteins. Journal of Cellular Physiology, 2002, 191, 1-16.	4.1	418
380	The FYVE domain in Smad anchor for receptor activation (SARA) is sufficient for localization of SARA in early endosomes and regulates TGFâ€Î²/Smad signalling. Genes To Cells, 2002, 7, 321-331.	1.2	137
381	Overexpression of Smad7 results in severe pathological alterations in multiple epithelial tissues. EMBO Journal, 2002, 21, 2580-2590.	7.8	100
382	Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors. EMBO Journal, 2002, 21, 1743-1753.	7.8	972
383	Bone morphogenetic protein receptors and their nuclear effectors in bone formation. , 2002, , 31-60.		5
384	Transforming growth factor beta signal transduction. Journal of Leukocyte Biology, 2002, 71, 731-40.	3.3	171
385	Phosphorylation of Smad Signaling Proteins by Receptor Serine/Threonine Kinases. , 2001, 124, 107-120.		25
386	Diffusion of Nodal Signaling Activity in the Absence of the Feedback Inhibitor Lefty2. Developmental Cell, 2001, 1, 127-138.	7.0	116
387	Transforming growth factor Î² signal transduction in hepatic stellate cells via Smad2/3 phosphorylation, a pathway that is abrogated during in vitro progression to myofibroblasts. FEBS Letters, 2001, 502, 4-10.	2.8	179
388	Ectopic expression of Smad7 inhibits transforming growth factor-Î² responses in vascular smooth muscle cells. Life Sciences, 2001, 69, 2641-2652.	4.3	13
389	Regulation of Smad signaling by protein kinase C. FASEB Journal, 2001, 15, 553-555.	0.5	170
390	Constitutive phosphorylation and nuclear localization of Smad3 are correlated with increased collagen gene transcription in activated hepatic stellate cells. Journal of Cellular Physiology, 2001, 187, 117-123.	4.1	111
391	Promoting bone morphogenetic protein signaling through negative regulation of inhibitory Smads. EMBO Journal, 2001, 20, 4132-4142.	7.8	160
392	Abnormal angiogenesis but intact hematopoietic potential in TGF-beta type I receptor-deficient mice. EMBO Journal, 2001, 20, 1663-1673.	7.8	488
393	Transforming growth factor-Î²-mediated mast cell migration depends on mitogen-activated protein kinase activity. Cellular Signalling, 2001, 13, 483-490.	3.6	53
394	Nodal Signaling Uses Activin and Transforming Growth Factor-Î² Receptor-regulated Smads. Journal of Biological Chemistry, 2001, 276, 656-661.	3.4	100
395	cDNA cloning, expression studies and chromosome mapping of human type I serine/threonine kinase receptor ALK7 (ACVR1C). Cytogenetic and Genome Research, 2001, 95, 157-162.	1.1	42
396	The Orphan Receptor Serine/Threonine Kinase ALK7 Signals Arrest of Proliferation and Morphological Differentiation in a Neuronal Cell Line. Journal of Biological Chemistry, 2001, 276, 5140-5146.	3.4	49

#	Article	IF	Citations
397	Interaction between GC Box Binding Factors and Smad Proteins Modulates Cell Lineage-specific Î±2(I) Collagen Gene Transcription. Journal of Biological Chemistry, 2001, 276, 16573-16579.	3.4	74
398	Activation of the TGF- Î² /Activin-Smad2 Pathway during Allergic Airway Inflammation. American Journal of Respiratory Cell and Molecular Biology, 2001, 25, 60-68.	2.9	121
399	Apoptosis in podocytes induced by TGF-Î² and Smad7. Journal of Clinical Investigation, 2001, 108, 807-816.	8.2	255
400	Apoptosis in podocytes induced by TGF-Î² and Smad7. Journal of Clinical Investigation, 2001, 108, 807-816.	8.2	534
401	Signal transduction mechanisms for members of the TGF-Î² family. , 2001, , 11-40.		3
402	Human mast cell migration in response to members of the transforming growth factor-Î² family. Journal of Leukocyte Biology, 2000, 67, 350-356.	3.3	108
403	Expression of the inhibitory Smad7 in early mouse development and upregulation during embryonic vasculogenesis. Developmental Dynamics, 2000, 218, 663-670.	1.8	20
404	Signaling of transforming growth factorâ€Î² family members through Smad proteins. FEBS Journal, 2000, 267, 6954-6967.	0.2	466
405	Functional consequences of tumorigenic missense mutations in the amino-terminal domain of Smad4. Oncogene, 2000, 19, 4396-4404.	5.9	86
406	Smad7 mediates apoptosis induced by transforming growth factor Î² in prostatic carcinoma cells. Current Biology, 2000, 10, 535-538.	3.9	149
407	Signaling inputs converge on nuclear effectors in TGF-Î² signaling. Trends in Biochemical Sciences, 2000, 25, 64-70.	7.5	340
408	Efficient TGF-Î² Induction of the Smad7 Gene Requires Cooperation between AP-1, Sp1, and Smad Proteins on the Mouse Smad7 Promoter. Journal of Biological Chemistry, 2000, 275, 29023-29030.	3.4	144
409	Role of Smad Proteins and Transcription Factor Sp1 in p21Waf1/Cip1 Regulation by Transforming Growth Factor-Î². Journal of Biological Chemistry, 2000, 275, 29244-29256.	3.4	347
410	Smad and AML Proteins Synergistically Confer Transforming Growth Factor Î²1 Responsiveness to Human Germ-line IgA Genes. Journal of Biological Chemistry, 2000, 275, 3552-3560.	3.4	136
411	The transcriptional co-activator P/CAF potentiates TGF-beta/Smad signaling. Nucleic Acids Research, 2000, 28, 4291-4298.	14.5	98
412	Activin receptor-like kinase 1 modulates transforming growth factor-Î²1 signaling in the regulation of angiogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 2626-2631.	7.1	785
413	Hedgehog Creates a Gradient of DPP Activity in Drosophila Wing Imaginal Discs. Molecular Cell, 2000, 5, 59-71.	9.7	375
414	Correlation between ALK-6 (BMPR-IB) Distribution and Responsiveness to Osteogenic Protein-1 (BMP-7) in Embryonic Mouse Bone Rudiments. Growth Factors, 2000, 17, 177-192.	1.7	20

#	Article	IF	Citations
415	TGF-Î² signaling by Smad proteins. Advances in Immunology, 2000, 75, 115-157.	2.2	410
416	Specificity, diversity, and regulation in TGFâ€Î² superfamily signaling. FASEB Journal, 1999, 13, 2105-2124.	0.5	725
417	Expression of TGF-beta related Smad proteins in human epithelial skin tumors.. International Journal of Oncology, 1999, 14, 1049-56.	3.3	17
418	Expression of Transforming Growth Factor-Î²1, Activin A, and Their Receptors in Thyroid Follicle Cells: Negative Regulation of Thyrocyte Growth and Function1. Endocrinology, 1999, 140, 4300-4310.	2.8	54
419	Eccrine Sweat Glands: Expression of Transforming Growth Factor-beta and Bone Morphogenetic Protein Type I Receptors and Their Intracellular Signalling Smad Proteins. Acta Dermato-Venereologica, 1999, 79, 183-186.	1.3	5
420	Differential Inhibition of Smad6 and Smad7 on Bone Morphogenetic Protein- and Activin-mediated Growth Arrest and Apoptosis in B Cells. Journal of Biological Chemistry, 1999, 274, 13637-13642.	3.4	201
421	An anchor for activation. Nature, 1999, 397, 109-111.	27.8	13
422	SMAD destruction turns off signalling. Nature Cell Biology, 1999, 1, E195-E197.	10.3	11
423	Localization of Smads, the TGF-Î² Family Intracellular Signaling Components During Endochondral Ossification. Journal of Bone and Mineral Research, 1999, 14, 1145-1152.	2.8	141
424	Chromosomal localization of three human genes encoding bone morphogenetic protein receptors. Mammalian Genome, 1999, 10, 299-302.	2.2	13
425	Functional antagonism between activin and osteogenic protein-1 in human embryonal carcinoma cells. , 1999, 180, 141-149.		43
426	Molecular analyses of the 15q and 18qSMAD genes in pancreatic cancer. , 1999, 24, 62-71.		53
427	Expression of transforming-growth-factor (TGF)-? receptors and Smad proteins in glioblastoma cell lines with distinct responses to TGF-?1. , 1999, 80, 756-763.		70
428	Expression of Smad proteins in human colorectal cancer. International Journal of Cancer, 1999, 82, 197-202.	5.1	99
429	Lack of responsiveness to TGF-Î²1 in a thyroid carcinoma cell line with functional type I and type II TGF-Î² receptors and Smad proteins, suggests a novel mechanism for TGF-Î² insensitivity in carcinoma cells. Molecular and Cellular Endocrinology, 1999, 153, 79-90.	3.2	25
430	Xenopus Smad4Î² Is the Co-Smad Component of Developmentally Regulated Transcription Factor Complexes Responsible for Induction of Early Mesodermal Genes. Developmental Biology, 1999, 214, 354-369.	2.0	88
431	Expression of Transforming Growth Factor-Â1, Activin A, and Their Receptors in Thyroid Follicle Cells: Negative Regulation of Thyrocyte Growth and Function. Endocrinology, 1999, 140, 4300-4310.	2.8	14
432	Expression of transformingâ€growthâ€factor (TGF)â€Î² receptors and Smad proteins in glioblastoma cell lines with distinct responses to TGFâ€Î²1. International Journal of Cancer, 1999, 80, 756-763.	5.1	2

#	Article	IF	Citations
433	Cartilage-Derived Morphogenetic Proteins and Osteogenic Protein-1 Differentially Regulate Osteogenesis. Journal of Bone and Mineral Research, 1998, 13, 383-392.	2.8	145
434	Direct binding of Smad3 and Smad4 to critical TGFbeta -inducible elements in the promoter of human plasminogen activator inhibitor-type 1gene. EMBO Journal, 1998, 17, 3091-3100.	7.8	1,637
435	Intracellular signaling of osteogenic protein-1 through Smad5 activation. , 1998, 177, 355-363.		73
436	Immunohistochemical detection of activin A, follistatin, and activin receptors during fracture healing in the rat. Journal of Orthopaedic Research, 1998, 16, 314-321.	2.3	32
437	Chromosomal localization of three human genes encoding members of the TGF-Î²2 superfamily of type I serine/threonine kinase receptors. Mammalian Genome, 1998, 9, 266-268.	2.2	9
438	Identification of receptors and Smad proteins involved in activin signalling in a human epidermal keratinocyte cell line. Genes To Cells, 1998, 3, 125-134.	1.2	68
439	Distinct and Overlapping Patterns of Localization of Bone Morphogenetic Protein (BMP) Family Members and a BMP Type II Receptor During Fracture Healing in Rats. Bone, 1998, 22, 605-612.	2.9	260
440	The L45 loop in type I receptors for TGF-Î²2 family members is a critical determinant in specifying Smad isoform activation. FEBS Letters, 1998, 434, 83-87.	2.8	352
441	Induction of Inhibitory Smad6 and Smad7 mRNA by TGF-Î²2 Family Members. Biochemical and Biophysical Research Communications, 1998, 249, 505-511.	2.1	323
442	Cloning and Characterization of p70S6KÎ²2Defines a Novel Family of p70 S6 Kinases. Biochemical and Biophysical Research Communications, 1998, 253, 470-476.	2.1	49
443	Identification of receptors and Smad proteins involved in activin signals in human epidermal keratinocytes. Journal of Dermatological Science, 1998, 16, S8.	1.9	0
444	SMAD3, SMAD4 and SMAD7 expression during murine hair follicle development and cycling. Journal of Dermatological Science, 1998, 16, S75.	1.9	0
445	Smad7 Is an Activin-inducible Inhibitor of Activin-induced Growth Arrest and Apoptosis in Mouse B Cells. Journal of Biological Chemistry, 1998, 273, 24293-24296.	3.4	119
446	Identification and Functional Characterization of a Smad Binding Element (SBE) in the JunB Promoter That Acts as a Transforming Growth Factor-Î²2, Activin, and Bone Morphogenetic Protein-inducible Enhancer. Journal of Biological Chemistry, 1998, 273, 21145-21152.	3.4	523
447	Transforming Growth Factor Î²2 1 Induces Nuclear Export of Inhibitory Smad7. Journal of Biological Chemistry, 1998, 273, 29195-29201.	3.4	218
448	Assignment¹ of the Smad7 gene (MADH7) to human chromosome 18q21.1 by fluorescence in situ hybridization. Cytogenetic and Genome Research, 1998, 81, 189-190.	1.1	20
449	Physical and Functional Interaction of Murine and Xenopus Smad7 with Bone Morphogenetic Protein Receptors and Transforming Growth Factor-Î²2 Receptors. Journal of Biological Chemistry, 1998, 273, 25364-25370.	3.4	143
450	Phosphorylation of Ser465 and Ser467 in the C Terminus of Smad2 Mediates Interaction with Smad4 and Is Required for Transforming Growth Factor-Î²2 Signaling. Journal of Biological Chemistry, 1997, 272, 28107-28115.	3.4	345

#	Article	IF	Citations
451	Transforming Growth Factor (TGF-Î²)-specific Signaling by Chimeric TGF-Î² Type II Receptor with Intracellular Domain of Activin Type IIB Receptor. Journal of Biological Chemistry, 1997, 272, 21187-21194.	3.4	31
452	Identification of Smad2, a Human Mad-related Protein in the Transforming Growth Factor Î² Signaling Pathway. Journal of Biological Chemistry, 1997, 272, 2896-2900.	3.4	149
453	Latent transforming growth factor-Î² complex in Chinese hamster ovary cells contains the multifunctional cysteine-rich fibroblast growth factor receptor, also termed E-selectin-ligand or MG-160. Biochemical Journal, 1997, 324, 427-434.	3.7	28
454	Expression and localization of bone morphogenetic proteins (BMPs) and BMP receptors in ossification of the ligamentum flavum. Bone, 1997, 21, 23-30.	2.9	98
455	Induction of Apoptosis by ASK1, a Mammalian MAPKKK That Activates SAPK/JNK and p38 Signaling Pathways. Science, 1997, 275, 90-94.	12.6	2,209
456	DPC4 (SMAD4) mediates transforming growth factor-Î²1 (TGF-Î²1) induced growth inhibition and transcriptional response in breast tumour cells. Oncogene, 1997, 14, 1891-1899.	5.9	132
457	TGF-Î² signalling from cell membrane to nucleus through SMAD proteins. Nature, 1997, 390, 465-471.	27.8	3,514
458	Identification of Smad7, a TGFÎ²-inducible antagonist of TGF-Î² signalling. Nature, 1997, 389, 631-635.	27.8	1,684
459	TGF-beta receptor-mediated signalling through Smad2, Smad3 and Smad4. EMBO Journal, 1997, 16, 5353-5362.	7.8	946
460	Orthotopic ossification of the spinal ligaments of zucker fatty rats: A possible animal model for ossification of the human posterior longitudinal ligament. Journal of Orthopaedic Research, 1997, 15, 820-829.	2.3	22
461	Characterization of a 60-kDa cell surface-associated transforming growth factor-Î² binding protein that can interfere with transforming growth factor-Î² receptor binding. Journal of Cellular Physiology, 1997, 173, 447-459.	4.1	24
462	Transforming Growth Factor-Î² Receptors and Signal Transduction. , 1997, , 277-284.		1
463	Bone morphogenetic protein receptors. Bone, 1996, 19, 569-574.	2.9	211
464	Follistatins neutralize activin bioactivity by inhibition of activin binding to its type II receptors. Molecular and Cellular Endocrinology, 1996, 116, 105-114.	3.2	185
465	Signaling via hetero-oligomeric complexes of type I and type II serine/threonine kinase receptors. Current Opinion in Cell Biology, 1996, 8, 139-145.	5.4	250
466	Phosphorylation of Ser165 in TGF-beta type I receptor modulates TGF-beta1-induced cellular responses.. EMBO Journal, 1996, 15, 6231-6240.	7.8	115
467	Bone morphogenetic protein type IB receptor is progressively expressed in malignant glioma tumours. British Journal of Cancer, 1996, 73, 624-629.	6.4	32
468	A Novel Type I Receptor Serine-Threonine Kinase Predominantly Expressed in the Adult Central Nervous System. Journal of Biological Chemistry, 1996, 271, 30603-30609.	3.4	68

#	Article	IF	Citations
469	Cloning and characterization of a human type II receptor for bone morphogenetic proteins.. Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 7632-7636.	7.1	507
470	A Rat Pituitary Tumor Cell Line (GH3) Expresses Type I and Type II Receptors and Other Cell Surface Binding Protein(s) for Transforming Growth Factor-Î². Journal of Biological Chemistry, 1995, 270, 770-774.	3.4	21
471	Efficient Association of an Amino-terminally Extended Form of Human Latent Transforming Growth Factor-Î² Binding Protein with the Extracellular Matrix. Journal of Biological Chemistry, 1995, 270, 31294-31297.	3.4	80
472	Osteogenic protein-1 binds to activin type II receptors and induces certain activin-like effects.. Journal of Cell Biology, 1995, 130, 217-226.	5.2	463
473	Expression of type I and type IB receptors for activin in midgestation mouse embryos suggests distinct functions in organogenesis. Mechanisms of Development, 1995, 52, 109-123.	1.7	111
474	Enhanced expression of type I receptors for bone morphogenetic proteins during bone formation. Journal of Bone and Mineral Research, 1995, 10, 1651-1659.	2.8	154
475	Distinct spatial and temporal expression patterns of two type I receptors for bone morphogenetic proteins during mouse embryogenesis. Endocrinology, 1995, 136, 2652-2663.	2.8	79
476	Characterization of Type I Receptors for Transforming Growth Factor-Î² and Activin. Science, 1994, 264, 101-104.	12.6	544
477	Serine/threonine kinase receptors. Progress in Growth Factor Research, 1994, 5, 55-72.	1.6	72
478	Characterization of in Vivo Phosphorylation of Activin Type II Receptor. Biochemical and Biophysical Research Communications, 1993, 194, 1508-1514.	2.1	19
479	Regulation of the levels of three transforming growth factor Î² mRNAs by estrogen and their effects on the proliferation of human breast cancer cells. Molecular and Cellular Endocrinology, 1993, 97, 115-123.	3.2	47
480	Cloning of a TGF$beta; type I receptor that forms a heteromeric complex with the TGF$beta; type II receptor. Cell, 1993, 75, 681-692.	28.9	769
481	Characterization of the binding of transforming growth factor-beta 1, - beta 2, and -beta 3 to recombinant beta 1-latency-associated peptide. Molecular Endocrinology, 1992, 6, 694-702.	3.7	22
482	Recombinant transforming growth factor type beta 3: biological activities and receptor-binding properties in isolated bone cells.. Molecular and Cellular Biology, 1990, 10, 4473-4479.	2.3	100
483	Molecular Characterization of Transforming Growth Factor Type ?3. Annals of the New York Academy of Sciences, 1990, 593, 26-42.	3.8	34
484	Distinct transforming growth factor-beta (TGF-beta) receptor subsets as determinants of cellular responsiveness to three TGF-beta isoforms. Journal of Biological Chemistry, 1990, 265, 20533-20538.	3.4	302
485	Growth Factors For Wound Healing. Nature Biotechnology, 1989, 7, 793-798.	17.5	57
486	Identification of another member of the transforming growth factor type beta gene family.. Proceedings of the National Academy of Sciences of the United States of America, 1988, 85, 4715-4719.	7.1	286

#	Article	IF	Citations
487	Genomic characterization of the human DNA excision repair geneERCC-1. Nucleic Acids Research, 1987, 15, 9195-9214.	14.5	73
488	Low Transforming Growth Factor-Î² Pathway Activity in Cervical Adenocarcinomas. Frontiers in Oncology, 0, 12, .	2.8	3